Table 2.

Changes in clinical and metabolic variables in the subgroups with low and high liver fat change, in response to increased intake of SFA.

	Low liver fat change (<median)	High liver fat change (≥median)	P-value
Body weight, kg	1.7 (1.0 to 2.4)	2.1 (1.2 to 3.3)	0.16
Waist, cm	2.5 (0.5 to 4)	2 (1 to 5)	0.87
Liver fat, %	0.1 (−0.1 to 0.3)	1.6 (0.6 to 3.3)	<0.0001
VAT, L	0.19 (0.08 to 0.34)	0.35 (0.17 to 0.60)	0.01
TAT, L	1.7 (1.0 to 2.2)	2.1 (1.5 to 2.5)	0.23
Pancreas fat, %	−0.3 (−1.1 to 0.7)	0.7 (−0.5 to 1.9)	0.11
Lean tissue (MRI), L	0.3 (−0.1 to 0.8)	0.5 (−0.3 to 1.4)	0.34
Triglycerides, mmol/L	−0.1 (−0.2 to 0.0)	0.0 (−0.1 to 0.4)	0.05
Insulin, mU/L	−0.25 (−1.2 to 1.4)	1.4 (−0.2 to 3.5)	0.01
Glucose, mmol/L	0.1 (−0.2 to 0.2)	0.1 (−0.2 to 0.2)	0.67
HOMA-IR	−0.1 (−0.3 to 0.3)	0.3 (0.0–0.9)	0.01
ALT, μkat/L	0.02 (−0.05 to 0.05)	0.11 (−0.04 to 0.23)	0.03
γGT, μkat/L	0.0 (−0.02 to 0.01)	0.04 (−0.04 to 0.08)	0.06
Adiponectin, μg/mL	0.07 (−0.02 to 0.39)	0.02 (−0.01 to 0.08)	0.20

Data are median (IQR) and compared using Wilcoxon test. ALT, alanine aminotransferase; GT, glutamyltransferase; HOMA-IR, homeostatic model assessment of insulin resistance; MRI, magnetic resonance imaging; VAT, visceral adipose tissue; TAT, total adipose tissue.